Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 billion DKK ($11.9 billion). Net income for the quarter rose 14% to 29 ...

Novo Nordisk has reported new data with its long-acting human growth hormone (hGH) product Sogroya, showing it is at least as effective as its older drug Norditropin in various paediatric growth ...

Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion Danish crowns ($2.64 billion), declining 13% from the previous quarter, and below the 18.7 billion crowns expected by analysts.

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 currently. Several factors have contributed to this downward trend.

With its Q1 2025 results on Wednesday, Novo Nordisk (NVO) lowered its full-year outlook, but its shares were rising in European trading after the pharma giant projected a sales recovery for its ...

Hims & Hers teams up with Novo Nordisk to bundle Wegovy into a $599/month telehealth care plan. Investors see Amazon-like potential as Hims scales affordable healthcare through platform-based ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Don’t miss this ...